MAGISTRONI, VERA
MAGISTRONI, VERA
DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)
Mechanisms of resistance to imatinib in chronic myeloid leukemia (CML) patients in chronic phase (CP) who achieved durable complete cytogenetic responses (CCR)
2003 Piazza, R; Magistroni, V; Tornaghi, L; Andreoni, F; Bungaro, S; Cazzaniga, G; Biondi, A; Pogliani, E; Varella Garcia, M; Corneo, G; GAMBACORTI PASSERINI, C
Bim promoter is highly methylated in malignant lymphoid cell lines, leading to downregulation of Bim expression and protection from apoptosis
2005 Piazza, R; Magistroni, V; Andreoni, F; Franceschino, A; GAMBACORTI PASSERINI, C
Evidence for D276G and L364I Bcr-Abl mutations in Ph plus leukaemic cells obtained from patients resistant to Imatinib
2005 Piazza, R; Magistroni, V; Gasser, M; Andreoni, F; Galietta, A; Scapozza, L; GAMBACORTI PASSERINI, C
Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients
2005 Piazza, R; Magistroni, V; Andreoni, F; Franceschino, A; Tornaghi, L; Varella Garcia, M; Bungaro, S; Colnaghi, F; Corneo, G; Pogliani, E; GAMBACORTI PASSERINI, C
Response to ‘D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients’ by leguay et al
2005 Piazza, R; Magistroni, V; Franceschino, A; GAMBACORTI PASSERINI, C
In vitro and in vivo activity of SKI-606, a novel Abl/Src inhibitor, against imatinib resistant BCR-ABL plus neoplastic
2006 Puttini, M; Coluccia, A; Boschelli, F; Franceschino, A; Tomaghi, L; Ahmed, S; Redaelli, S; Piazza, R; Magistroni, V; Andreoni, F; Scapozza, L; Formelli, F; GAMBACORTI PASSERINI, C
BIM promoter is epigenetically silenced in malignant lymphoid cells, leading to downregulation of BIM expression and protection from apoptosis
2006 Magistroni, V; Piazza, R; Brambilla, C; Andreoni, F; Franceschino, A; Collini, P; GAMBACORTI PASSERINI, C
The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years
2006 Piazza, R; Magistroni, V; Franceschino, A; Andreoni, F; Tornaghi, L; Colnaghi, F; Corneo, G; Pogliani, E; GAMBACORTI PASSERINI, C
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells
2006 Puttini, M; Coluccia, A; Boschelli, F; Cleris, L; Marchesi, E; Donella Deana, A; Ahamed, S; Redaelli, S; Piazza, R; Magistroni, V; Andreoni, F; Scapozza, L; Formelli, F; GAMBACORTI PASSERINI, C
Epigenetic changes at the bim locus associated with glucocorticoid resistance in human lymphoid malignancies
2007 Piazza, R; Magistroni, V; Bachmann, P; Gorman, R; Lock, R; GAMBACORTI PASSERINI, C
Mechanisms of Bim epigenetic silencing in anaplastic large cell lymphoma
2008 Piazza, R; Mogavero, A; Bachmann, P; Magistroni, V; Gorman, R; Lock, R; GAMBACORTI PASSERINI, C
Reversal of glucocorticoid resistance in human lymphoid malignancies with histone deacetylase inhibitors
2008 Piazza, R; Bachmann, P; Magistroni, V; Mogavero, A; Gorman, R; Marega, M; GAMBACORTI PASSERINI, C; Lock, R
Determination of the Activity Profile of Bosutinib, Dasatinib and Nilotinib against 18 Imatinib Resistant Bcr/Abl Mutants
2008 Redaelli, S; Piazza, R; Rostagno, R; Sassone, M; Magistroni, V; Perini, P; Marega, M; Boschelli, F; GAMBACORTI PASSERINI, C
Epigenetic Silencing of the Pro-Apoptotic Bim Gene in Glucocorticoid Poor-Responsive Pediatric Acute Lymphoblastic Leukemia, and Its Reversal by Histone Deacetylase Inhibition
2009 Lock, R; Bachmann, P; Piazza, R; Davies, C; James, M; Wong, N; Bhadri, V; Mogavero, A; Magistroni, V; GAMBACORTI PASSERINI, C; Saffery, R; Craig, J; Pimanda, J; Marshall, G
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants
2009 Redaelli, S; Piazza, R; Rostagno, R; Magistroni, V; Perini, P; Marega, M; GAMBACORTI PASSERINI, C; Boschelli, F
Role of TMPRSS2/ERG in cellular transformation
2009 Magistroni, V; Sanselicio, S; Mologni, L; Reid, J; Gariboldi, M; GAMBACORTI PASSERINI, C
Valproic acid enhances bosutinib cytotoxicity in colon cancer cells
2009 Mologni, L; Cleris, L; Magistroni, V; Piazza, R; Boschelli, F; Formelli, F; GAMBACORTI PASSERINI, C
Reactivation of an Epigenetic Silenced Tumor Suppressor Gene BIM in Anaplastic Large Cell Lymphoma Leads to massive Apoptosis
2010 Mogavero, A; Piazza, R; Magistroni, V; Marega, M; Collini, P; Ambrogio, C; Chiarle, R; GAMBACORTI PASSERINI, C
Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition
2010 Bachmann, P; Piazza, R; Janes, M; Wong, N; Davies, C; Mogavero, A; Bhadri, V; Szymanska, B; Geninson, G; Magistroni, V; Cazzaniga, G; Biondi, A; Miranda Saavedra, D; Göttgens, B; Saffery, R; Craig, J; Marshall, G; GAMBACORTI PASSERINI, C; Pimanda, J; Lock, R
Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2
2010 Mologni, L; Dekhil, H; Ceccon, M; Purgante, S; Lan, C; Cleris, L; Magistroni, V; Formelli, F; GAMBACORTI PASSERINI, C